We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
IMJUDO (AstraZeneca Pty Ltd)
Product name
IMJUDO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
219 (255 working days)
Active ingredients
tremelimumab
Registration type
NCE/NBE
Indication
Hepatocellular Carcinoma (HCC)
IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.